Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV), Eli Lilly & Co (LLY) and Johnson & Johnson (JNJ)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elevance Health (ELV – Research Report), Eli Lilly & Co (LLY – Research Report) and Johnson & Johnson (JNJ – Research Report).

Elevance Health (ELV)

Barclays analyst Steven Valiquette maintained a Buy rating on Elevance Health on March 24 and set a price target of $575.00. The company’s shares closed last Friday at $456.69.

According to TipRanks.com, Valiquette is a 1-star analyst with an average return of -2.0% and a 47.9% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, Bright Health Group, and Molina Healthcare.

Elevance Health has an analyst consensus of Strong Buy, with a price target consensus of $569.67, which is a 27.8% upside from current levels. In a report issued on March 24, Bank of America Securities also maintained a Buy rating on the stock with a $620.00 price target.

See today’s best-performing stocks on TipRanks >>

Eli Lilly & Co (LLY)

In a report issued on March 24, Carter Gould from Barclays reiterated a Buy rating on Eli Lilly & Co, with a price target of $400.00. The company’s shares closed last Friday at $336.13.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 2.1% and a 48.3% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Travere Therapeutics, and Gilead Sciences.

Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $375.23, which is a 12.7% upside from current levels. In a report issued on March 13, Wells Fargo also upgraded the stock to Buy with a $375.00 price target.

Johnson & Johnson (JNJ)

Bernstein analyst Lee Hambright maintained a Hold rating on Johnson & Johnson on March 23 and set a price target of $173.00. The company’s shares closed last Friday at $152.65.

According to TipRanks.com, Hambright is a 3-star analyst with an average return of 9.2% and a 65.0% success rate. Hambright covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Intuitive Surgical, and Abbott Labs.

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $179.22.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ELV:

• Elevance Health price target lowered to $580 from $610 at Truist
• 3 Best Stocks to Buy Now, 3/24/2023, According to Top Analysts
• Elevance Health price target lowered to $597 from $609 at Wells Fargo
• Elevance Health price target lowered to $571 from $581 at Deutsche Bank
• 10 Stocks to Buy Before Their Ex-Dividend Dates Arrive, Week of March 6, 2023